Navigation Links
Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
Date:2/17/2009

NEW HAVEN, Conn., Feb. 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced today that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its lead oncology therapeutic Onrigin (laromustine) Injection as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The Company has requested a priority review for the application and, if granted, Onrigin could receive approval for this indication in the second half of 2009.

Alan Kessman, Chief Executive Officer, commented, "This NDA filing is a significant milestone for Vion and for the Onrigin clinical development program. Acute myeloid leukemia is a devastating disease, and patients and their physicians are seeking new treatment options that can provide the opportunity for achieving a complete response." He concluded, "We are excited to be taking this major step towards achieving FDA approval for Onrigin."

The Onrigin NDA submission is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these patients had two or more risk factors that predicted for a poor prognosis. The Company presented data on this group of patients in a poster at the American Society of Hematology (ASH) Annual Meeting in December 2008.

Dr. Frank Giles, Chief of the Division of Hematology and Medical Oncology and Deputy Director of the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio commented, "If approved, Onrigin would represent an important new treatment option for elderly AML patients, many of whom now have no effective therapeutic option
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
5. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
6. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
7. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
8. Tigris Pharmaceuticals Files IND Application for GGTI-2418
9. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
10. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
11. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... During his lifetime Richard L. Sharp was ... himself with great people and take risks to achieve ... marveled at his extraordinarily courageous attitude when taking on ... even with his death impending—that’s how he continued looking ... ultimately take his life. , Carrying on Sharp’s relentless ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... 20, 2014 Offering a complete line ... Entris Balance promotion . The Sartorius Entris Balance is ... high accuracy, and easy-to-maintain balance entry level balance. , ... was designed to help customer’s bridge the gap between ... that is very durable. Sartorius is the second biggest ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.506 12/2001 , ... , , , , , ... , Cell type , ...
... , , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , , Protocol No. 4308 ... , , , , , , , , ... vinelandii, , , Cell type ...
... , , , , , , ... Protocol No. 4308 915.045 11/2001 , , , , , ... , Cell line , 721.82, EBV ... , , Transfection with , ...
Cached Biology Technology:Borrelia burgdorferi 2Azotobacter vinelandii 2721.82 2
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... model for human exercise? According an article published in the ... habits make it a prime model of cardiovascular fitness. The ... requirements, and, according to the authors, this cold-blooded snake may ... adapting to prolonged exercise and in response to some diseases. ...
... isolated the first human embryonic stem cell lines specifically tailored ... females of various ages, suffering from disease or spinal cord ... Science, which is published by AAAS, the non-profit science society, ... These cell lines will enable the study of human disease ...
... issue of Science holds mixed blessings for scientists who ... The study, conducted by scientists from Cincinnati Children's Hospital ... in Germany, reveals important evidence that tells us more ... other hand, scientists offer caution in regards to the ...
Cached Biology News:Scientists generate patient-specific stem cells, Science study says 2Scientists generate patient-specific stem cells, Science study says 3Scientists generate patient-specific stem cells, Science study says 4Science study holds implications for gene therapy and stem cell biology 2Science study holds implications for gene therapy and stem cell biology 3
... system, 220-240 V, is used for nucleic acid ... slab gel format. The system includes the modular ... separating nucleic acids with single base-pair resolution and ... and bonded inner glass plate, outer glass plate, ...
The imaging screen-K (Kodak), tritium, is a 20 x 25 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
... 2000 Capillary Electrophoresis System uses revolutionary ... electrophoresis (SPE), urine protein electrophoresis and ... accurate analysis. The system is truly ... and no staining to process patient ...
The external laser upgrade for the Molecular Imager FX adds a 635 nm external laser; the 555 nm long pass filter is replaced with a 605 nm band pass filter to distinguish Cy5 from 532 nm excitable dy...
Biology Products: